competitors better. This report also covers all the regions and countries of the world, which shows a
regional development status, including market size, volume and value, as well as price data.
The Global “Food Allergy Market” research 2019 highlights the major details and provides in-depth
analysis of the market along with the future growth, prospects and Industry demands analysis explores
with the help of complete report with 80 Pages, figures, graphs and table of contents to analyze the
situations of global Food Allergy Market and Assessment to 2028.
Food allergy is an abnormal response caused by food product such as tree nuts, peanut, soy. The
symptoms of allergic response could range from simple itchiness, tongue swelling, or hives to low blood
pressure, diarrhea or vomiting. fish allergies are more commonly found in Asia in comparison to the
western countries. In addition, rising awareness about food allergy, the high unmet needs coupled with
novel product introduction in the market are some other factors contributing to growth of the market in
near future.
Food Allergy Market Covers the Table of Contents With Segments, Key Players And Region. Based on
allergen source, Food Allergy Market is sub segmented into gluten, peanut, mustard, milk, egg, fish, and
others. Based on treatment, the market is sub segmented into antihistamines treatment, adrenaline
treatment, oral immunotherapy, and others. Based on end-use, market is sub segmented into hospitals,
clinics, and Ambulatory Surgery Centers.
Major Players profiled in the Food Allergy Market report incorporate: Allergy Therapeutics, Matrixx
Initiatives, Inc., Astellas Pharma, Inc., Immunomic Therapeutics, Inc., Prota Therapeutics, Aimmune
Therapeutics, Aravax, Cambridge Allergy Ltd, and others.
Industry News:
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for
life-threatening food allergies, today announced that the Biologics License Application (BLA) for AR101
has been accepted for review by the U.S. Food and Drug Administration (FDA).
Aimmune is developing AR101 as a treatment to reduce the risk of anaphylaxis following accidental
exposure to peanut. The FDA granted AR101 Breakthrough Therapy Designation in June 2015 for
peanut-allergic children and adolescents ages 4-17, which was preceded by the granting of Fast Track
Designation in September 2014. Both of these programs support expedited review of new drugs and
biologics.
The FDA has informed Aimmune that the BLA will be reviewed under a twelve-month target review
period, as measured from the January 2019 start date. As a consequence, review of the BLA may take
until late January 2020. Aimmune is currently engaged in discussions with the FDA regarding the review
timeline for the AR101 BLA. The FDA expects to convene an advisory committee meeting to discuss the
application.